Guggenheim analyst Vamil Divan initiated coverage of Travere Therapeutics with a Buy rating and $37 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Travere Therapeutics price target lowered to $42 from $44 at Canaccord
- Travere Therapeutics announces $175M common stock offering
- Travere Therapeutics Announces Proposed Public Offering of Common Stock
- Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07)